Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:

About the Author

Russian Federation


1. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612–617.

2. Jibson MD. Medical education and the pharmaceutical industry: managing an uneasy alliance. Acad Psychiatry 2006;30:36–39.

3. Moynihan R. Doctors’ education: the invisible influence of drug company sponsorship. BMJ 2008;336:416–417.

4. Podolsky SH, Greene JA. A historical perspective of pharmaceutical promotion and physician education. JAMA 2008;300:831–833.

5. Lo B, Field MJ, eds. Conflict of Interest in Medical Research, Education, and Practice. Washing-ton: Institute of Medicine; 2009. ISBN: 978–0–309–13188–9.

6. EFPIA. EFPIA code on the promotion of prescription-only medicines to, and interactions with, health-care professionals, 2007. asp?PageID=559&DocID=3483 (20 January 2012).

7. FPMA. IFPMA Code of Pharmaceutical Marketing Practices 2006 Revision. Appendix 1. 2006.

8. ABPI. Code of practice for the pharmaceutical industry, 2006.

9. Organisation for Economic Co-operation and Development. Recommendation for Further Combating Bribery of Foreign Public Officials in International Business Transactions. Paris, France: OECD; 2009.,3343,en_2649_ 34859_2017813_1_1_1 _1,00.html (20 January 2012).

10. Hager M, Russell S, Fletcher SW, eds. Continuing education in the health professions: improving healthcare through lifelong learning. Proceedings of a conference sponsored by the Josiah Macy, Jr. Foundation. New York, 2008. ISBN 0–914362–49–6. (20 January 2012).

11. Mazmanian PE. Commercial support of continuing medical education in the United States: the politics of doubt, the value of studies. J Contin Educ Health Prof 2009;29:81–83.

12. Chimonas S, Rothman DJ. New federal guidelines for physician-pharmaceutical industry relations: the politics of policy formation. Health Aff (Millwood) 2005;24:949–960.

13. Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, Nissen SE, Osborn JE, Scully JH Jr, Thomson GE, Wofsy D. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009;301:1367– 1372.

14. Chren MM, Landefeld CS. Physicians’ behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684–689.

15. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373–380.

16. Hatton RC, Chavez ML, Jackson E, Maurey J, Barriere SL, Couchenour R, Evens RP, Gunning K, Hume AL, Hutchison LC, Matzke GR, Noviasky JA, Rospond RM, Kelloway JS, Stevenson JG, Van-derveen RP, Verme-Gibboney CN, Walters D. Pharmacists and industry: guidelines for ethical interactions. Pharmacotherapy 2008;28:410–420.

17. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385–1389.

18. Stelfox HT, Chua G, O’Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 1998;338:101–106.

19. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999;282:1453–1457.

20. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299:1800–1812.

21. Pellegrino ED, Relman AS. Professional medical associations: ethical and practical guidelines. JAMA 1999;282:984–986.

22. Ross JS, Coutts G, Tiner R, Angell M, Gottlieb S. Doctors, patients and the drug industry: partners, friends, or foes? BMJ 2009;338:326–329.

23. Harrington RA, Califf RM. There is a role for industry-sponsored education in cardiology. Circulation 2010;121:2221–2227.

24. Gelberman RH, Samson D, Mirza SK, Callaghan JJ, Pellegrini VD. Orthopaedic surgeons and the medical device industry: the threat to scientific integrity and the public trust. J Bone Joint Surg Am 2010;92:765–777.

25. Bruyere O, Kanis JA, Ibar-Abadie ME, Alsayed N, Brandi ML, Burlet N, Cahall DL, Chines A, Devogelaer JP, Dere W, Goel N, Hughes N, Kaufman JM, Korte S, Mitlak BH, Niese D, Rizzoli R, Rovati LC, Reginster JY. The need for a transparent, ethical, and successful relationship between academic scientists and the pharmaceutical industry: a view of the Group for the Respect of Ethics and Excellence in Science (GREES). Osteoporos Int 2010;21:713–722.

26. Drazen JM, Curfman GD. Financial associations of authors. N Engl J Med 2002;346:1901–1902.

27. Lexchin J, O’Donovan O. Prohibiting or ‘managing’ conflict of interest? A review of policies and procedures in three European drug regulation agencies. Soc Sci Med 2010;70: 643–647.

28. Association of American Medical Colleges. Industry Funding of Medical Education. Report of an AAMC Task Force. Washington, DC: AAMC; 2008. publications/showfile.cfm?file=version114.pdf.

29. European Commission, SEC(2010) 1161. Communication from the Commission to the Euro-pean Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions. Europe 2020 Flagship Initiative. Innovation Union. Brussels, 6.1.2010. unioncommunication_en.pdf.

30. Merkur S, Mossialos E, Long M, McKee M. Physician revalidation in Europe. Clin Med 2008;8:371–376.

31. Maisonneuve H, Matillon Y, Negri A, Pallares L, Vigneri R, Young HL. Continuing medical education and professional revalidation in Europe: five case examples. J Contin Educ Health Prof 2009;29:58–62.

32. Fras Z, Destrebecq F, Creplet C, Welling C. Survey of European CME/CPD. Continuing Medical Education and Professional Development. Brussels: European Union of Medicine Specialists (UEMS); 2008. (20 January 2012).

33. Garattini L, Gritti S, De Compadri P, Casadei G. Continuing medical education in six European countries: a comparative analysis. Health Policy 2010;94:246–254.

34. Desbois EJ, Pardell H, Negri A, Kellner T, Posel P, Kleinoeder T, Maillet B, Maisonneuve H. Continuing medical education in Europe: evolution or revolution, 2010. http://www (20 January 2012).

35. Organisme Gestionnaire Conventionnel. Rapport d’activite´ FPC (Formation professionnelle con-ventionnelle) 2009;10–11.

36. Royal College of Physicians. (RCP). Innovating for health: patient, physicians, the pharmaceutical industry and the NHS. Report of a Working Party, 2009. http://–76c5–4ab3–89a0–92d44e45edc3.pdf.

37. Netherlands Federation of University Medical Centres. Collective agreement for University Medical Centres, 1 January 2008–1 March 2011. NFU–083083, article 15.9.1.

38. Accreditation Council for Continuing Medical Education (ACCME). Annual Report Data 2008.–246a–4e8e–91d3d24ff2f5bfec_up-loaddocument.pdf.

39. American Heart Association. AHA annual report 2009. (20 January 2012).

40. Camilleri M, Parke DW 2nd. Perspective: conflict of interest and professional organizations: considerations and recommendations. Acad Med 2010;85:85–91.

41. Criteria for international accreditation of CME. European Union of Medical Specialists, 2007.

42. Fletcher S. Pharma and CME: view from the US. BMJ 2008;337:a1023.

43. Davis DA, Thompson MA, Oxman AD, Haynes B. Changing physician performance: a systematic review of the effect of continuing medical education strategies. JAMA 1995;274: 700–705.

44. Davis D, O’Brien MAT, Freemantle N, Wolf FM, Mazmanian P, Taylor-Vaisey A. Impact of formal continuing medical education. Do conferences, workshops, rounds, and other traditional continuing education activities change physician behavior or health care outcomes? JAMA 1999;282:867–874.

45. Bowen Judith L. Medical education: educational strategies to promote clinical diagnostic reasoning. N Engl J Med 2006;355:2217–2225.

46. Kahn N. Industry support and professional medical associations—letter to the editor. JAMA 2009;302:737.

47. Smith CD, Buyske J, Talamini MA. Industry support and professional medical associations—letter to the editor. JAMA 2009;302:738–739.

48. Coyle SL. Physician-industry relations. Part 1: individual physicians. Ann Intern Med 2002;136:396–402.

49. Coyle SL. Physician-industry relations. Part 2: organizational issues. Ann Intern Med 2002;136:403–406.

50. European Medicines Agency (EMA). Policy on the Handling of Conflicts of Interests of Management Board and Scientific Committee Members and EMEA Experts. London: EMA; 2006. http ://

51. Boyd EA, Bero LA. Improving the use of research evidence in guideline development: 4. Managing conflicts of interest. Health Res Policy Syst 2006;4:16.

52. Guyatt G, Akl EA, Hirsh J, Kearon C, Crowther M, Gutterman D, Lewis SZ, Nathanson I, Jaeschke R, Schu¨nemann H. The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med 2010;152:738–741.

53. Mitchell PB. Winds of change: growing demands for transparency in the relationship between doctors and the pharmaceutical industry. Med J Aust 2009;191:273–275.

54. Schu¨nemann HJ, Osborne M, Moss J, Manthous C, Wagner G, Sicilian L, Ohar J, McDermott S, Lucas L, Jaeschke R; ATS Ethics and Conflict of Interest Committee and the Documents Development and Implementation Committee. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med 2009;180:564–580.

55. International Committee of Medical Journal Editors. Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest. ICMJE; 2009. http://www. (20 January 2012).

For citation:


Views: 918

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)